The Risk Of Misuse & Diversion Of Buprenorphine For Opioid Use Disorder Appears To Be Low In Medicare Part D

On May 17, 2023, the U.S. Department of Health and Human Services (HHS) published this report that finds that the risk of misuse and diversion of buprenorphine for "opioid use disorder" appears to be low in those with Medicare Part D. This data brief provides information related to the risk of misuse and diversion of buprenorphine in Medicare Part D in 2021—prior to the repeal of the Drug Addiction Treatment Act (DATA) waiver of 2000 . . .